949922-27-4

Usage

Uses

Used in Organic Synthesis:
1-(1,2,3,4-Tetrahydroisoquinolin-6-yl)ethanone is used as a building block in organic synthesis for the creation of various pharmaceuticals, agrochemicals, and other fine chemicals. Its unique tetrahydroisoquinoline ring structure allows for the development of a wide range of compounds with diverse applications.
Used as a Reagent in Chemical Reactions:
In chemical reactions, 1-(1,2,3,4-Tetrahydroisoquinolin-6-yl)ethanone serves as a reagent to introduce the tetrahydroisoquinoline group into other molecules. This capability is valuable for the synthesis of complex organic compounds and the modification of existing molecules to enhance their properties or create new functionalities.
Target for Research and Development of New Drugs and Therapeutic Agents:
Due to its potential biological and pharmacological properties, 1-(1,2,3,4-Tetrahydroisoquinolin-6-yl)ethanone is a target for research in the development of new drugs and therapeutic agents. Its unique structure and reactivity make it a promising candidate for the creation of innovative pharmaceuticals and treatments for various diseases and conditions.

Upstream product

• 158984-84-0 6-trifluoromethanesulfonyloxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 158984-83-9 N-tert-butoxycarbonyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 371222-34-3 tert-butyl 6-(Methoxy(methyl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 170097-67-3 2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid 
• 1008518-35-1 tert-butyl 6-acetyl-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 111-34-2 -butyl vinyl ether 

Downstream Products

• 1254062-81-1 1-[2-(4-cyclopropylmethoxybenzyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]ethanone 

Relevant academic research and scientific papers

GPR103 antagonists demonstrating anorexigenic activity in vivo: Design and development of pyrrolo[2,3- c ]pyridines that mimic the c-terminal arg-phe motif of QRFP26

GPR103, a G-protein coupled receptor, has been reported to have orexigenic properties through activation by the endogenous neuropeptide ligands QRFP26 and QRFP43. Recognizing that central administration of QRFP26 and QRFP43 increases high fat food intake in rats, we decided to investigate if antagonists of GPR103 could play a role in managing feeding behaviors. Here we present the development of a new series of pyrrolo[2,3-c]pyridines as GPR103 small molecule antagonists with GPR103 affinity, drug metabolism and pharmacokinetics and safety parameters suitable for drug development. In a preclinical obesity model measuring food intake, the anorexigenic effect of a pyrrolo[2,3-c]pyridine GPR103 antagonist was demonstrated. In addition, the dynamic 3D solution structure of the C-terminal heptapeptide of the endogenous agonist QRFP26 (20-26) was determined using NMR. The synthetic pyrrolo[2,3-c] pyridine antagonists were compared to this experimental structure, which displayed a possible overlay of pharmacophore features supportive for further design of GPR103 antagonists.

INHIBITORS OF ACETYL-COA CARBOXYLASE

The present invention relates to compounds that act as acetyl-CoA carboxylase (ACC) inhibitors. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES

Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues of the Formula: are provided, in which variables are as described herein. Such compounds may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are parti